Endo's New Chief Has Challenges Ahead
As Firm's US Generics Sales Continue To Suffer
Executive Summary
Set to take charge of the company on 6 March, Endo's incoming chief Blaise Coleman must tackle Endo's multi-billion-dollar debt and steer the firm back to profitability after several years of significant losses.
You may also be interested in...
Endo’s Par Delivers On Nevakar Alliance With First Launch
Endo’s Par has announced the first launch under a longstanding US collaboration with 505(b)(2) specialist Nevakar, in the form of pre-mixed ephedrine sulfate injection in a ready-to-use 50mg/10ml single-use vial.
Who’s Hired? Endo Names New CEO
Endo has named a new CEO and CFO, while Mylan and Pfizer’s Viatris has found its CFO and announced its full roster of board members. Meanwhile, Assogenerici names the leaders of its value added medicines sector group, law firm Fish & Richardson gets a new CEO and France appoints a new health minister.
Endo Starts Search For Campanelli’s Successor
With Endo’s CEO Paul Campanelli intending to step down for personal reasons, the US brands and generics player’s board has started to look for external and internal candidates to take over.